Table 1.
Description of Clinical Sample Population. Values presented as mean ± s.e. with range (min, max) or percent. Average length on treatment refers to antipsychotic or mood stabilizer. BMI = Body Mass Index; * reflects the number of months that have elapsed since the medication was first prescribed.
| Atypical Antipsychotic (n = 8) | Mood Stabilizer (n = 8) | p-Value | |
|---|---|---|---|
| Age (years) | 45.5 ± 5.1 (26, 61) | 43.3 ± 3.6 (30, 58) | 0.7 |
| Race (% Caucasian/% African American) | 50.0/37.5 | 75.0/12.5 | 0.3 |
| Sex (% female) | 37.5 | 50 | 0.6 |
| BMI (mg/kg2) | 29.7 ± 2.4 (19.6, 41.7) | 31.0 ± 1.4 (25.6, 35.5) | 0.6 |
| Body fat % | 34.4 ± 2.3 (27.3, 43.8) | 34.6 ± 2.0 (27.0, 42.9) | 0.9 |
| Fasting Glucose (mg/dL) | 91.3 ± 3.4 (75.3, 102) | 93.5 ± 3.1 (84, 109) | 0.8 |
| Fasting Insulin (uU/mL) | 25.7 ± 12.3 (5.4, 103.3) | 12.9 ± 1.7 (7.5, 22.9) | 0.4 |
| HOMA-IR | 6.5 ± 3.3 (1.2, 27.9) | 2.9 ± 0.4 (1.5, 5.1) | 0.5 |
| Glucose AUC | 15,850.4 ± 560.0 (13,884.8, 17,905.5) | 17,088 ± 1336.1 (11,187.0, 21,712.5) | 0.4 |
| Insulin AUC | 8505.8 ± 2386.3 (2863.5, 23,309.0) | 5612.2 ± 742.5 (2597.1, 8699.6) | 0.4 |
| Duration of Current Antipsychotic or Mood Stabilizer Therapy (months) * | 94.1 ± 28.8 (3, 228) | 58.6 ± 21.6 (6, 180) | 0.3 |
| Years Since First Psychopharmacologic Treatment | 23.1 ± 3.9 (7, 37) | 19.1 ± 3.2 (6, 33) | 0.4 |